Chimeric Therapeutics Limited Stock Net Income
| CHMMF Stock | 0 0.00 0.00% |
Chimeric Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Chimeric Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Chimeric Therapeutics' valuation are provided below:Chimeric Therapeutics Limited does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Chimeric |
Chimeric Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Chimeric Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Chimeric Therapeutics.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Chimeric Therapeutics on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Chimeric Therapeutics Limited or generate 0.0% return on investment in Chimeric Therapeutics over 90 days. More
Chimeric Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Chimeric Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Chimeric Therapeutics Limited upside and downside potential and time the market with a certain degree of confidence.
Chimeric Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chimeric Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Chimeric Therapeutics' standard deviation. In reality, there are many statistical measures that can use Chimeric Therapeutics historical prices to predict the future Chimeric Therapeutics' volatility.Chimeric Therapeutics Backtested Returns
We have found three technical indicators for Chimeric Therapeutics Limited, which you can use to evaluate the volatility of the firm. The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Chimeric Therapeutics are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
Chimeric Therapeutics Limited has no correlation between past and present. Overlapping area represents the amount of predictability between Chimeric Therapeutics time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Chimeric Therapeutics price movement. The serial correlation of 0.0 indicates that just 0.0% of current Chimeric Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Chimeric Therapeutics Limited reported net income of (15.9 Million). This is much lower than that of the sector and significantly lower than that of the Net Income industry. The net income for all United States stocks is notably higher than that of the company.
Chimeric Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chimeric Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Chimeric Therapeutics could also be used in its relative valuation, which is a method of valuing Chimeric Therapeutics by comparing valuation metrics of similar companies.Chimeric Therapeutics is currently under evaluation in net income category among its peers.
Chimeric Fundamentals
| Return On Equity | -0.63 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (5.57) % | |||
| Current Valuation | 56.81 K | |||
| Shares Outstanding | 437.09 M | |||
| Shares Owned By Insiders | 47.75 % | |||
| Price To Book | 1.49 X | |||
| Price To Sales | 10.02 X | |||
| Revenue | 2.62 M | |||
| Gross Profit | 2.62 M | |||
| EBITDA | (14.14 M) | |||
| Net Income | (15.9 M) | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (13.15 M) | |||
| Market Capitalization | 26.23 M | |||
| Total Asset | 34.88 M | |||
| Net Asset | 34.88 M |
About Chimeric Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chimeric Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chimeric Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chimeric Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Chimeric Pink Sheet
Chimeric Therapeutics financial ratios help investors to determine whether Chimeric Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Chimeric with respect to the benefits of owning Chimeric Therapeutics security.